We are a global team dedicated to improve the lives of patients with Fragile X Syndrome and Autism Spectrum Disorder. Our work spans three decades of research in neuroscience and intellectual disabilities. The “mGluR theory of fragile X” proposed by MIT Professor Mark Bear and collaborators in 2004 is widely considered to be a key conceptual breakthrough, and laid the foundation for development of disease-modifying therapies for treatment of Fragile X Syndrome and Autism Spectrum Disorder. Allos Pharma is committed to develop and market the first approved therapy in Fragile X Syndrome.

The name Allos Pharma is derived from
allistic, meaning not autistic.

Allos Pharma

Mads Emil Matthiesen

This department oversees compliance with laws and regulations, ensuring that the organization meets required standards.

Allos Pharma

Org chart

Teams

Regulatory Affairs

Offices